Dermelle’s Nanotechnology

SEM image used with permission by Dr. Sheila Grant
Proven Technical Advantages

1. Decreased Degradation
2. Promotion of rebuilding collagen
3. Antioxidant & antimicrobial properties

Significance:

Longer lasting products with superior efficacy
Commercialization Plan:

Proof of Concept & Animal Preliminary Studies

Product Development & Optimization

Initial Target Market

Cosmetic Surgery
Injectable Nanomaterial-Collagen Dermal Filler to treat facial wrinkles

Future Applications

- Urological: (Incontinence)
- Radiant Burns (Skin Corrections)
- Hemostatic Dressing (Wound Healing)
- Cardiovascular (Coronary Implants)
- Orthopedic (Prosthetics Implants)

Worldwide Dermal Filler Product Sales
- 3.4 million procedures
- $760 million in product sales

9% Annual Growth Rate
Competitive Landscape

<table>
<thead>
<tr>
<th>Product</th>
<th>Durability of Augmentation</th>
<th>Gentleness &amp; Biocompatibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artefill* (Dsc'd)</td>
<td>5 years or more</td>
<td></td>
</tr>
<tr>
<td>Sculptra</td>
<td>2-3 years</td>
<td></td>
</tr>
<tr>
<td>Radiesse</td>
<td>12 - 18 months</td>
<td></td>
</tr>
<tr>
<td>Restylane</td>
<td>12 months</td>
<td></td>
</tr>
<tr>
<td>Juverderm Evolence* (Dsc'd)</td>
<td>3 - 6 months</td>
<td></td>
</tr>
<tr>
<td>Prevelle Hydrelle</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Competitive Advantages

<table>
<thead>
<tr>
<th>Usability</th>
<th>Performance</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Easy to inject</td>
<td>• Long Lasting</td>
<td>• Nonallergenic</td>
</tr>
<tr>
<td>• Affordable to patient &amp; physician</td>
<td>• Few local adverse effects</td>
<td></td>
</tr>
<tr>
<td>• Does not migrate after injection</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Value Proposition:

Dermal Filler with 2 year duration and fewer side effects than competition.
Dermelle Team

- Interim CEO
  - Luis Jimenez, MBA 2011
- CSO
  - Rebecca J. Rone, MS, Co-Founder
- COO
  - Anthony N Harris, MD, MBA, Co-Founder
- Key Researchers
  - Sheila Grant, PhD, Co-Founder
  - David Grant, Co-Founder
- Scientific Advisory Board
  - Ron Wheeland, MD
Timeline & Milestones

<table>
<thead>
<tr>
<th>Feasibility &amp; Concept</th>
<th>Design &amp; Development</th>
<th>Design Verification</th>
<th>Pre-Clinical Testing</th>
<th>Clinical Testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milestone</td>
<td>Milestone</td>
<td>Milestone</td>
<td>Milestone</td>
<td>Milestone</td>
</tr>
</tbody>
</table>

- **Pre-Clinical Testing**
  - **Cell Culture Assay**
  - **Benchtop Analysis**
  - **Preliminary Animal Study**
  - **Optimization w/ Contract Manufacturer**

- **Product Development**
  - **Pre-Clinical Testing**
    - **Cell Culture Assay**
    - **Benchtop Analysis**
    - **Preliminary Animal Study**
    - **Optimization w/ Contract Manufacturer**

- **Clinical Testing**
  - **2 Year Animal Study w/ CRO**
  - **Human Clinical Trials**
    - **CE Mark**
    - **OEM Partnership w/ Manufacturer**

- **Funding**
  - **Q1’10** $120K MUBIP
  - **Q1’11** $500K Angel
  - **Q3’11** $7.5M Series A Venture Capital (Two Tranches)
  - **Q1’12** $3.5M
  - **Q3’12** $4M

- **Milestone**
  - **Q1’10** $120K MUBIP
  - **Q3’10** $500K Angel
  - **Q1’11** $7.5M Series A Venture Capital (Two Tranches)
  - **Q3’12** Patent Conversion
  - **Q1’12** CE Mark
  - **Q3’12** OEM Partnership w/ Manufacturer

COMPLETE
Dermelle, LLC

Q&A
Dermelle’s Business Model

1. Current
   - Addressable Clinical Need
   - Market Opportunity Verification
   - Tissue Engineered Solution

2. 2nd Milestone
   - Human Clinical Trial
   - Animal Trial
   - Product Development & Optimization

3. 3rd Milestone
   - OEM Manufacturing Provider
   - Market Specific Exclusive License with Leading Manufacturer
   - Future Application

4. Future Application
   - Market Specific Exclusive License with Leading Manufacturer

- Current Milestone
- 1st Milestone
- 2nd Milestone
- 3rd Milestone